ホームページ Cytoskeletal Signaling Myosin

Myosin

Myosin製品

  • All (2)
  • Myosin阻害剤 (1)
  • Myosin活性剤(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2623 Omecamtiv mecarbil (CK-1827452) Omecamtiv mecarbil (CK-1827452) は、特定の心臓Myosinアクチベーターであり、左心室収縮性心不全の臨床薬です。フェーズ2。
Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6
Eur Heart J, 2025, ehaf813
Journal of General Physiology, 2025, e202513762
Omecamtiv-S2623Y0120150109.gif
E6493New MT-125 MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.
E6493New MT-125 MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.
S2623 Omecamtiv mecarbil (CK-1827452) Omecamtiv mecarbil (CK-1827452) は、特定の心臓Myosinアクチベーターであり、左心室収縮性心不全の臨床薬です。フェーズ2。
Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6
Eur Heart J, 2025, ehaf813
Journal of General Physiology, 2025, e202513762
 Omecamtiv-S2623Y0120150109.gif
E6493New MT-125 MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.